Related Experiment Videos
EQUIL93: a tool for experimental and clinical urolithiasis
C M Brown1, D K Ackermann, D L Purich
1Department of Biochemistry and Molecular Biology, University of Florida College of Medicine, Gainesville 32610-0245.
Urological Research
|January 1, 1994
Summary
The updated EQUIL93 software enhances the study of biomineralization and urolithiasis. This version offers expanded applications for crystal growth, nucleation, and stone risk assessment in research and therapeutic evaluations.
Area of Science:
- Biomineralization
- Urolithiasis research
- Physicochemical processes
Background:
- The EQUIL software, previously EQUIL2, is a widely used tool for studying urolithiasis and biomineralization.
- Previous versions focused on physicochemical processes of stone salt crystallization, including crystal growth and nucleation.
Purpose of the Study:
- To describe the extensively updated EQUIL93 software.
- To highlight the expanded scope and new applications of the enhanced software.
- To demonstrate the utility of EQUIL93 in stone risk assessments.
Main Methods:
- Description of software enhancements in EQUIL93.
- Illustration of new applications beyond the urologic realm.
- Discussion of the software's role in in vivo research and therapeutic evaluation.
Main Results:
- EQUIL93 offers an expanded scope of application compared to EQUIL2.
- The software facilitates studies on crystal growth and nucleation.
- New applications, including those outside urology, have been developed.
Conclusions:
- The enhanced EQUIL93 software provides a more versatile tool for biomineralization and urolithiasis research.
- EQUIL93 can aid in in vivo research, therapeutic evaluation, and stone risk assessments.
- The updated software has broader applicability in physicochemical and clinical studies.